Leerink Partners Lowers Teladoc Health (NYSE:TDOC) Price Target to $5.50

Teladoc Health (NYSE:TDOC) had its price target lowered by Leerink Partners from $8.50 to $5.50 in a research note issued to investors on Thursday,Benzinga reports. The brokerage currently has a “market perform” rating on the health services provider’s stock. Leerink Partners’ price target would suggest a potential upside of 4.70% from the company’s previous close.

Other equities research analysts also recently issued reports about the stock. Bank of America upgraded shares of Teladoc Health from a “neutral” rating to a “buy” rating and set a $7.00 target price on the stock in a research report on Thursday. Zacks Research downgraded shares of Teladoc Health from a “strong-buy” rating to a “hold” rating in a research note on Monday, November 10th. BMO Capital Markets reduced their price objective on shares of Teladoc Health from $8.00 to $5.00 and set a “market perform” rating on the stock in a research note on Thursday. Weiss Ratings restated a “sell (e+)” rating on shares of Teladoc Health in a report on Monday, December 29th. Finally, Stifel Nicolaus cut their target price on Teladoc Health from $8.00 to $6.00 and set a “hold” rating on the stock in a report on Thursday. Four analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Teladoc Health presently has a consensus rating of “Hold” and a consensus target price of $7.80.

Teladoc Health Stock Down 1.8%

Shares of NYSE:TDOC opened at $5.25 on Thursday. Teladoc Health has a 52-week low of $4.40 and a 52-week high of $9.94. The company has a market capitalization of $932.25 million, a PE ratio of -4.61 and a beta of 2.12. The company has a debt-to-equity ratio of 0.71, a quick ratio of 2.60 and a current ratio of 2.70. The company has a fifty day moving average of $5.99 and a 200-day moving average of $7.20.

Teladoc Health (NYSE:TDOC) last issued its earnings results on Wednesday, February 25th. The health services provider reported ($0.14) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.05. Teladoc Health had a negative return on equity of 9.09% and a negative net margin of 7.92%.The business had revenue of $642.27 million during the quarter, compared to analysts’ expectations of $635.33 million. During the same quarter in the prior year, the firm earned ($0.28) EPS. The business’s revenue for the quarter was up .3% compared to the same quarter last year. Teladoc Health has set its Q1 2026 guidance at -0.450–0.350 EPS and its FY 2026 guidance at -1.100–0.700 EPS. On average, equities analysts predict that Teladoc Health will post -1.16 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, insider Carlos Nueno sold 3,897 shares of the firm’s stock in a transaction that occurred on Tuesday, December 2nd. The stock was sold at an average price of $7.49, for a total transaction of $29,188.53. Following the completion of the sale, the insider owned 27,175 shares of the company’s stock, valued at $203,540.75. This trade represents a 12.54% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Fernando M. Rodrigues sold 4,209 shares of Teladoc Health stock in a transaction that occurred on Wednesday, December 3rd. The stock was sold at an average price of $7.48, for a total value of $31,483.32. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 33,288 shares of company stock valued at $251,684. 0.58% of the stock is currently owned by insiders.

Institutional Trading of Teladoc Health

Several large investors have recently modified their holdings of TDOC. Alpine Global Management LLC bought a new stake in shares of Teladoc Health in the 4th quarter valued at $187,000. Virtu Financial LLC acquired a new stake in Teladoc Health in the fourth quarter worth $854,000. Corient Private Wealth LLC increased its stake in Teladoc Health by 236.6% in the fourth quarter. Corient Private Wealth LLC now owns 37,692 shares of the health services provider’s stock valued at $264,000 after purchasing an additional 26,494 shares in the last quarter. Mackenzie Financial Corp increased its stake in Teladoc Health by 38.6% in the fourth quarter. Mackenzie Financial Corp now owns 165,550 shares of the health services provider’s stock valued at $1,157,000 after purchasing an additional 46,090 shares in the last quarter. Finally, Empowered Funds LLC raised its holdings in shares of Teladoc Health by 1.9% during the fourth quarter. Empowered Funds LLC now owns 742,305 shares of the health services provider’s stock valued at $5,196,000 after purchasing an additional 14,029 shares during the period. Institutional investors and hedge funds own 76.82% of the company’s stock.

Trending Headlines about Teladoc Health

Here are the key news stories impacting Teladoc Health this week:

• Positive Sentiment: Q4 beat and narrower loss — Teladoc posted Q4 revenue of $642.3M (above Street) and a GAAP loss of $0.14/sh that was better than expected; management highlighted international and Integrated Care strength that helped offset weakness at BetterHelp. Teladoc Tops Q4 Earnings
• Positive Sentiment: Medium‑term revenue guidance and strategic initiatives — Management projected 2026 revenue of $2.47B–$2.59B and emphasized AI, insurance partnerships and international expansion as growth levers. That gives investors a multi‑year growth narrative beyond the quarter. 2026 Revenue Projection
• Positive Sentiment: Some analyst support remains — Bank of America upgraded TDOC to Buy (PT $7) and a few firms (Canaccord, Piper Sandler) kept positive/overweight stances despite trimming targets, signaling conviction among some analysts that upside exists from current levels. Analyst Reviews
• Neutral Sentiment: Earnings call details and metrics — Management’s earnings call and transcript provide context on segment trends (Integrated Care up, BetterHelp down) and KPI performance; useful for assessing sustainability of the beat. Earnings Call Highlights
• Negative Sentiment: Near‑term guidance and outlook caution — Q1 revenue guide (~$609M) and FY EPS guidance were conservative and Q1 revenue guidance came in below some estimates, creating uncertainty over short‑term growth and profitability. Q4 & Guidance Release
• Negative Sentiment: Multiple price‑target cuts — Several firms trimmed targets (examples: BMO to $5.00, Leerink to $5.50, Cowen/Wells Fargo/Stifel to $6.00 ranges), and some moved to market‑perform/hold — this fresh downdraft from sell‑side revisions pressures sentiment despite the beat. Analyst Target Moves

About Teladoc Health

Teladoc Health, Inc is a leading global provider of virtual healthcare services, offering on-demand medical consultations via phone, video, and mobile app platforms. The company connects patients with licensed physicians and specialists for non-emergency medical issues, mental health support, dermatology, and chronic condition management. By leveraging digital technologies and data analytics, Teladoc aims to enhance accessibility, reduce healthcare costs, and improve patient outcomes through personalized care plans and remote monitoring.

Teladoc’s service portfolio includes general medical visits, behavioral health sessions, expert medical services for complex cases, and wellness programs designed to support chronic disease management such as diabetes, hypertension, and heart disease.